肿瘤手术病人外周静脉输液性静脉炎发生风险预测模型的构建

Construction of the risk prediction model for infusion phlebitis of peripheral vein in patients undergoing tumor surgery

目的:构建肿瘤手术病人外周静脉输液性静脉炎发生风险预测模型。方法:选取2021年4月—2022年9月在我院手术室行外科手术的肿瘤住院病人1178例作为研究对象,采用前瞻性研究设计,收集病人一般资料及手术相关资料并随访至病人术后72 h。以美国静脉输液护理学会的输液性静脉炎分级标准作为评价标准,采用单因素分析及Logistic回归分析探讨病人外周静脉发生输液性静脉炎的影响因素,并建立回归方程。结果:1178例病人中67例发生输液性静脉炎,发生率为5.69%,术后6 h~24 h发生率最高。Logistic回归分析显示,肿瘤病人吸烟史、穿刺部位、穿刺肢体、一次穿刺、输液加温进入回归方程,并构建病人外周静脉输液性静脉炎风险预测模型,模型校准度良好。结论:构建的肿瘤手术病人外周静脉输液性静脉炎发生风险预测模型具有良好的预测性能,可以为临床早期识别肿瘤手术病人输液性静脉炎发生风险提供参考。

Objective:To construct the risk prediction model for infusion phlebitis of peripheral vein in patients undergoing tumor surgery.Methods:A total of 1178 cancer inpatients who underwent surgical operations in the operating room of our hospital from April 2021 to September 2022 were selected as the study objects.A prospective study design was adopted.General and surgical data of patients were collected,and patients were followed up to 72 hours after surgery.Using the grading standard of infusion phlebitis of the American Society for Intravenous Infusion Nursing as the evaluation standard,univariate analysis and Logistic regression analysis were used to explore the influencing factors of infusion phlebitis in patients with peripheral veins,and the regression equation was established.Results:There were 67 patients with infusion phlebitis of peripheral vein,accounting to 5.69%,with the highest incidence from 6 hours to 24 hours after operation.Logistic regression analysis showed that smoking history of tumor patients,puncture site,puncture limb,one puncture and whether infusion heating were entered into the regression equation.The risk prediction model of patients with peripheral intravenous infusion phlebitis was established,and the model was calibrated well.Conclusions:The established risk prediction model for infusion phlebitis of peripheral vein in patients undergoing tumor surgery had good predictive performance.It can provide reference for early clinical identification of the risk of infusion phlebitis in patients undergoing tumor surgery.